{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:21:55Z","timestamp":1785842515872,"version":"3.56.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007075","name":"European Society for Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.ctrv.2015.03.001","type":"journal-article","created":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T03:17:18Z","timestamp":1426216638000},"page":"301-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["Targeted agents for cancer treatment during pregnancy"],"prefix":"10.1016","volume":"41","author":[{"given":"Matteo","family":"Lambertini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedro A.","family":"Peccatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Hatem A.","family":"Azim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2015.03.001_b0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/IGC.0b013e3181a1d0ec","article-title":"Gynecologic cancers in pregnancy: guidelines of an international consensus meeting","volume":"19","author":"Amant","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ctrv.2015.03.001_b0010","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.ejca.2010.09.010","article-title":"Breast cancer in pregnancy: recommendations of an international consensus meeting","volume":"46","author":"Amant","year":"2010","journal-title":"Eur J Cancer"},{"issue":"Suppl. 6","key":"10.1016\/j.ctrv.2015.03.001_b0015","doi-asserted-by":"crossref","first-page":"vi160","DOI":"10.1093\/annonc\/mdt199","article-title":"Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Peccatori","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10549-008-0159-2","article-title":"Weekly epirubicin in the treatment of gestational breast cancer (GBC)","volume":"115","author":"Peccatori","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2015.03.001_b0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/PPO.0b013e3181ce46f9","article-title":"Breast cancer during pregnancy: maternal and fetal outcomes","volume":"16","author":"Cardonick","year":"2010","journal-title":"Cancer J"},{"key":"10.1016\/j.ctrv.2015.03.001_b0030","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S1470-2045(12)70261-9","article-title":"Treatment of breast cancer during pregnancy: an observational study","volume":"13","author":"Loibl","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0035","unstructured":"National Toxicology Program. NTP Monograph: Developmental Effects and Pregnancy Outcomes Associated With Cancer Chemotherapy Use During Pregnancy. NTP Monogr 2013:i\u2013214."},{"key":"10.1016\/j.ctrv.2015.03.001_b0040","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ctrv.2009.11.004","article-title":"Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors","volume":"36","author":"Azim","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2015.03.001_b0045","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/bdrb.20201","article-title":"An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies","volume":"86","author":"Pentsuk","year":"2009","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0050","unstructured":"Comprehensive Cancer Information \u2013 National Cancer Institute. Available at: <http:\/\/www.cancer.gov\/> [accessed February 25, 2015]."},{"key":"10.1016\/j.ctrv.2015.03.001_b0055","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.breast.2011.06.009","article-title":"Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis","volume":"20","author":"Valachis","year":"2011","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2015.03.001_b0060","article-title":"Trastuzumab containing regimens for early breast cancer","volume":"4","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2015.03.001_b0065","article-title":"Trastuzumab-containing regimens for metastatic breast cancer","volume":"6","author":"Balduzzi","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2015.03.001_b0070","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/378394a0","article-title":"Requirement for neuregulin receptor erbB2 in neural and cardiac development","volume":"378","author":"Lee","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2015.03.001_b0075","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1089\/dna.2004.23.807","article-title":"Application of a gene vaccine targeting HER-2\/neu in immunocontraception","volume":"23","author":"Ni","year":"2004","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0080","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10549-012-1996-6","article-title":"Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01\u201301)","volume":"133","author":"Azim","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2015.03.001_b0085","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10549-012-2368-y","article-title":"Trastuzumab administration during pregnancy: a systematic review and meta-analysis","volume":"137","author":"Zagouri","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2015.03.001_b0090","first-page":"953","article-title":"Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues","volume":"5","author":"Press","year":"1990","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2015.03.001_b0095","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/BF00852567","article-title":"Expression of the epidermal growth factor receptor in fetal kidney","volume":"7","author":"Goodyer","year":"1993","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/376337a0","article-title":"Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor","volume":"376","author":"Miettinen","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2015.03.001_b0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/8773","article-title":"Epidermal growth factor receptor function is necessary for normal craniofacial development and palate closure","volume":"22","author":"Miettinen","year":"1999","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2015.03.001_b0110","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3816\/CBC.2006.n.048","article-title":"Delivery of a healthy baby after first-trimester maternal exposure to lapatinib","volume":"7","author":"Kelly","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2015.03.001_b0115","first-page":"1426","article-title":"The effects of rituximab treatment during pregnancy on a neonate","volume":"91","author":"Friedrichs","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2015.03.001_b0120","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1470-2045(06)70797-5","article-title":"Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy","volume":"7","author":"Decker","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0125","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.03.001_b0130","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1200\/JCO.2013.49.8220","article-title":"Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis","volume":"31","author":"Evens","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0135","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.03.001_b0140","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.jp.7211665","article-title":"Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk","volume":"27","author":"Russell","year":"2007","journal-title":"J Perinatol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0145","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00404-008-0861-7","article-title":"Imatinib use during pregnancy and breast feeding: a case report and review of the literature","volume":"280","author":"Ali","year":"2009","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ctrv.2015.03.001_b0150","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.6004\/jnccn.2009.0069","article-title":"Issues of imatinib and pregnancy outcome","volume":"7","author":"Apperley","year":"2009","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"10.1016\/j.ctrv.2015.03.001_b0155","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.03.001_b0160","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2141.1996.02330.x","article-title":"Successful treatment of acute promyelocytic leukaemia with all-trans-retinoic-acid during late pregnancy","volume":"94","author":"Lipovsky","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0165","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000087893","article-title":"Plasma all-trans retinoic acid level in neonates of mothers with acute promyelocytic leukemia","volume":"114","author":"Takitani","year":"2005","journal-title":"Acta Haematol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0170","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/tera.1420450106","article-title":"Teratogenicity of all-trans retinoic acid during early embryonic development in the cynomolgus monkey (Macaca fascicularis)","volume":"45","author":"Hendrickx","year":"1992","journal-title":"Teratology"},{"key":"10.1016\/j.ctrv.2015.03.001_b0175","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/bdra.20721","article-title":"The neurobehavioral teratology of retinoids: a 50-year history","volume":"88","author":"Adams","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0180","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1096-8652(199610)53:2<145::AID-AJH19>3.0.CO;2-E","article-title":"All-trans retinoic acid-induced labor in a pregnant patient with acute promyelocytic leukemia","volume":"53","author":"Sham","year":"1996","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/cncr.21137","article-title":"Acute leukemia during pregnancy: a report on 37 patients and a review of the literature","volume":"104","author":"Chelghoum","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2015.03.001_b0190","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1365-2141.1994.tb04811.x","article-title":"Successful use of all-trans retinoic acid in acute promyelocytic leukaemia presenting during the second trimester of pregnancy","volume":"86","author":"Harrison","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0195","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/ijgc-00009577-200207000-00012","article-title":"Transient dilated cardiomyopathy in a newborn exposed to idarubicin and all-trans-retinoic acid (ATRA) early in the second trimester of pregnancy","volume":"12","author":"Siu","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ctrv.2015.03.001_b0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000264183","article-title":"Pharmacokinetics of interferon-alpha in pregnant women and fetoplacental passage","volume":"10","author":"Pons","year":"1995","journal-title":"Fetal Diagn Ther"},{"key":"10.1016\/j.ctrv.2015.03.001_b0205","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1600-0609.1996.tb00497.x","article-title":"Two cases of CML treated with alpha-interferon during second and third trimester of pregnancy with analysis of the drug in the new-born immediately postpartum","volume":"57","author":"Haggstrom","year":"1996","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0210","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.lungcan.2009.10.006","article-title":"Lung cancer in the pregnant woman: to treat or not to treat, that is the question","volume":"67","author":"Azim","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.03.001_b0215","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jnci\/djt072","article-title":"Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis","volume":"105","author":"Lee","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2015.03.001_b0220","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0896-6273(00)80937-X","article-title":"Response diversity and the timing of progenitor cell maturation are regulated by developmental changes in EGFR expression in the cortex","volume":"19","author":"Burrows","year":"1997","journal-title":"Neuron"},{"key":"10.1016\/j.ctrv.2015.03.001_b0225","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/ki.1997.336","article-title":"Receptor protein tyrosine kinases in perinatal developing rat kidney","volume":"52","author":"Kee","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.ctrv.2015.03.001_b0230","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1515\/JPEM.1994.7.4.295","article-title":"Epidermal growth factor receptor and human fetoplacental development","volume":"7","author":"Evain-Brion","year":"1994","journal-title":"J Pediatr Endocrinol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0235","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1210\/en.2004-0588","article-title":"Epidermal growth factor family members: endogenous mediators of the ovulatory response","volume":"146","author":"Ashkenazi","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2015.03.001_b0240","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1210\/me.2005-0185","article-title":"Role of the epidermal growth factor network in ovarian follicles","volume":"20","author":"Conti","year":"2006","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0245","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.lungcan.2007.10.025","article-title":"Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy","volume":"60","author":"Zambelli","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.03.001_b0250","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.lungcan.2011.08.008","article-title":"Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure","volume":"74","author":"Lee","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.03.001_b0255","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.lungcan.2012.03.026","article-title":"Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma","volume":"77","author":"Rivas","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.03.001_b0260","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.lungcan.2014.06.003","article-title":"Efficacy and safety of gefitinib during pregnancy: case report and literature review","volume":"85","author":"Gil","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.03.001_b0265","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.placenta.2011.04.008","article-title":"Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models","volume":"32","author":"Led\u00f3n","year":"2011","journal-title":"Placenta"},{"key":"10.1016\/j.ctrv.2015.03.001_b0270","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2217\/imt.13.64","article-title":"Are monoclonal antibodies a safe treatment for cancer during pregnancy?","volume":"5","author":"Sarno","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ctrv.2015.03.001_b0275","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/380439a0","article-title":"Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene","volume":"380","author":"Ferrara","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2015.03.001_b0280","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.acthis.2007.02.008","article-title":"Vasculogenesis and angiogenesis in the early human placenta","volume":"109","author":"Demir","year":"2007","journal-title":"Acta Histochem"},{"key":"10.1016\/j.ctrv.2015.03.001_b0285","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jsgi.2003.09.002","article-title":"Vascular endothelial growth factor activation of intramembranous absorption: a critical pathway for amniotic fluid volume regulation","volume":"11","author":"Cheung","year":"2004","journal-title":"J Soc Gynecol Investig"},{"key":"10.1016\/j.ctrv.2015.03.001_b0290","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1472-6483(10)60487-7","article-title":"Vascular endothelial growth factor gene polymorphism and implantation failure","volume":"16","author":"Goodman","year":"2008","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.ctrv.2015.03.001_b0295","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1254\/jphs.09299FP","article-title":"Effects of KRN633, an inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase, on vascular development of placenta and fetus of mid-pregnancy in mice","volume":"112","author":"Wada","year":"2010","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.ctrv.2015.03.001_b0300","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.03.001_b0305","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/bdrb.20194","article-title":"Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo\u2013fetal development in rats and rabbits","volume":"86","author":"Patyna","year":"2009","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0310","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/bdrb.21026","article-title":"Embryo\u2013fetal transfer of bevacizumab (Avastin) in the rat over the course of gestation and the impact of neonatal Fc receptor (FcRn) binding","volume":"95","author":"Thorn","year":"2012","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0315","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3109\/14767058.2013.879645","article-title":"Effect of anti-vascular endothelial growth factor antibody during early fetal development in rats","volume":"27","author":"Kaygusuz","year":"2014","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.ctrv.2015.03.001_b0320","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/eye.2008.218","article-title":"Exposure to verteporfin and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy","volume":"23","author":"Rosen","year":"2009","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ctrv.2015.03.001_b0325","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/IAE.0b013e3181f57d58","article-title":"Intravitreal bevacizumab during pregnancy","volume":"30","author":"Tarantola","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ctrv.2015.03.001_b0330","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1111\/j.1755-3768.2009.01572.x","article-title":"Early loss of pregnancy after intravitreal bevacizumab injection","volume":"88","author":"Petrou","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0335","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/eye.2013.311","article-title":"Intravitreal bevacizumab injection in unrecognised early pregnancy","volume":"28","author":"Sullivan","year":"2014","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ctrv.2015.03.001_b0340","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1124\/dmd.108.022764","article-title":"Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats","volume":"36","author":"He","year":"2008","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"10.1016\/j.ctrv.2015.03.001_b0345","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3230.3230","article-title":"Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2015.03.001_b0350","doi-asserted-by":"crossref","first-page":"136252","DOI":"10.1155\/2010\/136252","article-title":"Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy","volume":"2010","author":"Conchon","year":"2010","journal-title":"Adv Hematol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0355","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.05.2010.2975","article-title":"Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester","volume":"2010","author":"Bayraktar","year":"2010","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ctrv.2015.03.001_b0360","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3109\/10428194.2010.497982","article-title":"Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib","volume":"51","author":"Kroll","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2015.03.001_b0365","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/CAD.0b013e328352a8fe","article-title":"A dramatic fetal outcome following transplacental transfer of dasatinib","volume":"23","author":"Berveiller","year":"2012","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ctrv.2015.03.001_b0370","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1756-8722-2-42","article-title":"Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study","volume":"2","author":"Conchon","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0375","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2015.03.001_b0380","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1200\/JCO.2012.45.2870","article-title":"Treatment of metastatic malignant melanoma with vemurafenib during pregnancy","volume":"31","author":"Maleka","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.03.001_b0385","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2005.10.014","article-title":"Cancer and pregnancy: poena magna, not anymore","volume":"42","author":"Pentheroudakis","year":"2006","journal-title":"Eur J Cancer"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215000468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215000468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:19:26Z","timestamp":1759655966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737215000468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0305737215000468"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.03.001","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted agents for cancer treatment during pregnancy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}